Projects per year
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2017 2024
A phase 2 study of venetoclax in combination with low-dose cytarabine in relapsing acute myeloid leukemia.
Wei, A., Tiong, I. S., Reynolds, J. & Kennedy, N.
22/09/19 → 31/12/24
Project: Research
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) versus Epoetin Alfa for the Treatment of Anemia due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naive Subjects who require Red Blood Cell Transfusions.
Tiong, I. S. & Kennedy, N.
15/07/19 → 31/12/24
Project: Research
Establishing a Monash Partners national reference centre for molecular monitoring of residual disease (MRD) in acute myeloid leukaemia
Wei, A., Ivey, A., Fleming, S. A., Tiong, I. S., McManus, J. & Ting, S.
1/01/17 → 31/12/19
Project: Research
Research Output 2017 2019
17
Citations
(Scopus)
Combining BH3-Mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
Moujalled, D. M., Pomilio, G., Ghiurau, C., Ivey, A., Salmon, J., Rijal, S., Macraild, S., Zhang, L., Teh, T. C., Tiong, I. S., Lan, P., Chanrion, M., Claperon, A., Rocchetti, F., Zichi, A., Kraus-Berthier, L., Wang, Y., Halilovic, E., Morris, E., Colland, F. & 7 others, , 1 Apr 2019, In : Leukemia. 33, a, p. 905-917 13 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access
File
1
Citation
(Scopus)
Dissecting causes for improved survival among patients with acute myeloid leukemia in two different eras receiving identical regimens in sequential randomized studies
Tiong, I. S., Reynolds, J., Bradstock, K. F., Seymour, J. F., Wei, A. H. & on behalf of the Australasian Leukaemia & Lymphoma Group, 22 Aug 2018, In : Blood Cancer Journal. 8, 9, 5 p., 84.Research output: Contribution to journal › Letter › Research › peer-review
Open Access
File
Molecular Patterns of Response and Outcome in the Chemotherapy and Venetoclax in Elderly AML Trial (CAVEAT) study. Blood 2018 132:333
Wei, A., Chua, C. C., Tiong, I. S., Fong, C. Y., Ting, S. B. N., Macraild, S., Salmon, J. M., Ivey, A., Nguyen, J., Yuen, F., Fleming, S. A., Bohlander, S., Reynolds, J. & Roberts, A. W., Dec 2018.Research output: Contribution to conference › Abstract
Open Access
Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia
Tiong, I. S., Tan, P., McManus, J., Cummings, N., Sadawarte, S., Catalano, J., Hills, R. & Wei, A., 2018, In : Leukemia and Lymphoma. 59, 2, p. 493-496 4 p.Research output: Contribution to journal › Letter › Research › peer-review
The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study
Tan, P., Tiong, I. S., Fleming, S., Pomilio, G., Cummings, N., Droogleever, M., McManus, J., Schwarer, A., Catalano, J., Patil, S., Avery, S., Spencer, A. & Wei, A., 2017, In : Oncotarget. 8, 32, p. 52269-52280 12 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access